A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age (NCT06693895)
A Phase 3a, Observer-blind, Randomized, Controlled Study to Evaluate the Safety of an Investigational Varicella Vaccine Compared With Varivax, Administered as a First Dose to Healthy Children 12 to 15 Months of Age
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess how well-tolerated GSK's investigational varicella vaccine (VNS Vaccine) is, in comparison to an already approved varicella vaccine (VV) known as Varivax. The study will be conducted on healthy children aged 12 to 15 months, and who have neither contracted varicella nor received a varicella vaccination.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Phoenix, Arizona
Age range: 12 Months to 15 Months
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (46 Sites)
Showing the first 25 of 46 sites.
- GSK Investigational Site — Phoenix, Arizona
- GSK Investigational Site — Tucson, Arizona
- GSK Investigational Site — Huntington Park, California
- GSK Investigational Site — National City, California
- GSK Investigational Site — West Covina, California
- GSK Investigational Site — Hialeah, Florida
- GSK Investigational Site — Miami, Florida
- GSK Investigational Site — Chicago, Illinois
- GSK Investigational Site — El Dorado, Kansas
- GSK Investigational Site — Lafayette, Louisiana
- GSK Investigational Site — Mankato, Minnesota
- GSK Investigational Site — Lincoln, Nebraska
- GSK Investigational Site — Cincinnati, Ohio
- GSK Investigational Site — Dallas, Texas
- GSK Investigational Site — Dallas, Texas
- GSK Investigational Site — Houston, Texas
- GSK Investigational Site — Richmond, Texas
- GSK Investigational Site — Richmond, Texas
- GSK Investigational Site — San Antonio, Texas
- GSK Investigational Site — Roy, Utah
- GSK Investigational Site — Syracuse, Utah
- GSK Investigational Site — Richmond, Virginia
- GSK Investigational Site — Vienna, Virginia
- GSK Investigational Site — Burgas,
- GSK Investigational Site — Gabrovo,
📞 Contact the Study Coordinator
Phone: (877) 379-3718
Email: GSKClinicalSupportHD@gsk.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chickenpox
- A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age — Salvaleón de Higüey, La Altagracia Province
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age — Mobile, Alabama
- A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age — Tucson, Arizona
Explore by condition: All Chickenpox clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.